InMed's Eric Hsu and Michael Woudenberg among Event's Expert Speakers
VANCOUVER, Aug. 29, 2019 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, today announced that executives of the Company will participate in the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit ("iCDP"). The iCDP will be held September 10-12, 2019 in Boston, MA, USA, at the Aloft Boston Seaport hotel. Eric Hsu, Senior Vice President, Preclinical Research and Development and Michael Woudenberg, Vice President, Chemistry, Manufacturing, and Control will be featured Expert Speakers.
Dr. Eric Hsu will participate on a panel on Wednesday, September 11th at 5:00pm EST titled "The Potential Effects Biosynthesis Could Have on the Cannabinoid-Derived Pharmaceuticals Development Process and the Wider Industry." Dr. Hsu is considered an expert in gene transfer and gene expression using vector systems, the foundation of any biosynthesis process. His industry experience includes discovery research, formulation development and manufacturing process development.
Mr. Michael Woudenberg will participate on a panel discussion on Wednesday, September 11th at 12:15pm EST titled "Whole Plant Vs. Synthetic Cannabinoids and their Relative Potential in Pharmaceuticals." Mr. Woudenberg has extensive experience in process and formulation development of products derived from plant-based extraction and chemical synthesis at commercial scale.
Eric A. Adams, President and Chief Executive Officer of InMed, said, "We are excited to attend the 2nd Annual iCDP conference, and are proud that two members of our executive team have been selected as panelists." Mr. Adams continued, "Michael and Eric are experts in their field, and look forward to discussing not only the significant progress being made at InMed, but also the increasing global understanding of the potential of cannabinoid-based therapeutics."
For more information on the conference, please visit www.international-cdp.com.
InMed Pharmaceuticals is a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids, as well as a pipeline of medications that target diseases with high unmet medical needs. For more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs; and Dr. Hsu and Mr. Woudenberg participating in the iCDP as Expert Speakers.
With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Dr. Hsu's and Mr. Woudenberg's continued availability to participate in the iCDP; continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for InMed's products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the iCDP presentations may not occur as planned, or at all; clinical trials may not proceed as anticipated; economic or market conditions may worsen; and InMed's proprietary biosynthesis manufacturing process and drug development programs may not deliver the expected level of results. A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed's most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.
For further information: Investor Contact: InMed Pharmaceuticals Inc., Bruce Colwill, Chief Financial Officer, T: +1.604.669.7207, E: [email protected]; Edison Advisors for InMed Pharmaceuticals, Joe Green, Senior Vice President, T: +1.646.653.7030, E: [email protected]